3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDIV
1
Study Type
Observational
1
Sponsor
Cancer Type
Tumor-Agnostic
2
Gastrointestinal
2
Thoracic
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Prostatic Neoplasms
24
Carcinoma, Renal Cell
11
Kidney Neoplasms
8
Neoplasm Metastasis
5
Lung Neoplasms
5
Colorectal Neoplasms
5
Colonic Neoplasms
5
Wilms Tumor
4
Pancreatic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Hepatocellular
4
Urinary Bladder Neoplasms
3
Testicular Neoplasms
3
Rectal Neoplasms
3
Breast Neoplasms
3
Testicular Germ Cell Tumor
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Mesothelioma, Malignant
2
Melanoma
2
Liver Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Medullary
2
Interventions
pembrolizumab
6
Radiosurgery
5
Docetaxel
5
enzalutamide
4
darolutamide
3
Radiotherapy
3
Everolimus
3
Androgen Antagonists
3
relugolix
2
luprolide acetate gel depot
2
Surveys and Questionnaires
2
Standard of Care
2
Radiotherapy, Image-Guided
2
Radiofrequency Ablation
2
Panobinostat
2
Leuprolide
2
Abiraterone Acetate
2
trastuzumab deruxtecan
1
talazoparib
1
spartalizumab
1
siremadlin
1
sipuleucel-T
1
sargramostim
1
resiquimod
1
polysaccharide-K
1
poly ICLC
1
palbociclib
1
olaparib
1
liposomal doxorubicin
1
ixabepilone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
sargramostim
×
Genitourinary
×
Clear all
NCT03695835
2020-07-22
NIRPA
Gary Onik MD
Completed
27 enrolled